weight loss drug news today glp-1 october 2025 New Daily Pill Aims to Take on Ozempic GLP-1 Weight-Loss Drug Demonstration Begins

coverage for weight loss varies by insurer, plan type, and documented medical necessity criteria

Identical Pharmacy eligibility criteria to SGLT-2 inhibitor Empagliflozin, but funding is either or Some patient could benefit from both SGLT-2 inhibitor and GLP-1 agonists

According to 2020 ADA guidance ( Figure 2 ), and in consideration of JMs established ASCVD, the addition of a GLP-1 RA with evidence of cardiovascular benefit to JMs regimen could be considered

Pfizer laid off around 210 employees across two sites in North Carolina this year (150 at Sanford and another 60 in Rocky Mount)

GLP-1RAs, specifically liraglutide, have also been evaluated for their effects on cardiovascular biomarkers